InterCure has received NHS stamp for its non-drug, non-invasive hypertension treatment device, RESPeRATE.

RESPeRATE, a respiratory modulator used by patients for just 15 minutes a day, at least four times a week, is proven to lower the blood pressure (BP).

RESPeRATE was approved after a six-month review of its ten supporting clinical studies (five of which were randomised, controlled), patient satisfaction analyses and cost-benefit economic models.

InterCure said its RESPeRATE has also met all of the Department of Health’s (DoH) requirements for safety, quality, appropriateness and cost effectiveness.

InterCure CSO and RESPeRATE inventor Benjamin Gavish said they are delighted that patients in the UK can now obtain RESPeRATE on prescription.

"We hope that this move by the NHS to set up a new device category to supplement the currently available treatment options for hypertension will encourage GPs to integrate RESPeRATE into their hypertension standard of care," Gavish said.